Category: RVA News

The much-awaited key findings from the Australian Rare Disease Registry Audit project, led by Monash University registry experts, Professor Susannah Ahern and Dr Rasa Ruseckaite, are in. Rare Voices Australia (RVA) is overseeing this critical work in recognition of the importance of rare disease registries (RDRs), which is acknowledged in the Australian Government’s National Strategic Action Plan for Rare Diseases (the Action Plan). Thank you to the rare disease community for your genuine interest in this work and to all RVA Partners and registry managers who dedicated their time to participate in the survey and interviews. Your contributions have shaped this important first step towards a national approach to RDRs in Australia.

The importance of RDRs

The Action Plan highlights that in Australia, data for most rare diseases is not captured in either health information systems or registries and there is no coordinated strategy to collect, measure, build and translate data that does exist.

Registries have the capacity to:
• facilitate public reporting and knowledge building
• reveal differences in care practices and process and the impact of both on patients
• identify best practice and target areas for future improvement
• reveal information about incidence, prevalence, epidemiology, impact, treatment outcomes, the natural history of diseases and much more.

Why is a national approach to rare disease registries so important?

The challenges of rare disease registries are multifaceted and complex. In line with the Action Plan, a national approach to rare disease registries is vital because it is not practical or economically feasible to create clinical quality registries for every rare disease.

Implementation step 3.1.4.1. in the Action Plan outlines the first step to achieve a national approach:

Develop a summary report of all existing Australian and relevant international rare disease registries, collecting information on:
• governance standards;
• management practices;
• data sets, including patient numbers, estimated incidence, prevalence and coverage; and
• classification systems used (for interoperability with other registries and health information
systems).

This information will support national coordination of rare disease registries and the establishment of minimum data sets, to provide a better understanding of who is currently being counted and aid identification of best practice.

Rare Disease Registry Audit

Objectives

The Rare Disease Registry Audit progresses the work outlined in Implementation step 3.1.4.1. in the Action Plan.

The objectives of this project were to highlight the ‘current state of play’ of RDRs in Australia, including what RDRs exist nationally, how they are funded, what they do with their data and their impact on patient outcomes. Other areas addressed through consultation with existing Australian RDRs included barriers and enablers to setting up sustainable RDRs, perceptions about the future potential for RDRs to improve clinical outcomes and ideas for the way forward.

Key Findings

Key Finding 1: Data collected by RDRs

• 43% collect information related to treatments
• 50% collect clinical/diagnostic information
• 50% collect demographic data
• 25% collect information related to adverse events
• 43% collect Patient Reported Outcome Measures (PROMS)/Quality of Life Measures (QoL)

Key Finding 2: Uses of data collected by RDRs

• 45% use data for research (e.g. clinical trials, epidemiological modelling, collaborative projects, secondary data)
• 12% use data for post-marketing surveillance for high-cost medicines
• 32% produce publications

Key finding 3: Impact of RDR’s not measured

The impact of rare disease registries is not routinely measured. The study showed there are clear examples of RDRs having a positive impact.

The Australian Cystic Fibrosis Data Registry (ACFDR) for example, is a long-standing, clinician led international cystic fibrosis (CF) registry, established in 1996. ACFDR has benefited from strong community support and advocacy by former Australian Health Ministers. This support has allowed ACFDR to capture data from over 3,500 people (over 90% of Australians) living with CF. ACFDR has played a crucial role in:

• improving clinical outcomes
• facilitating recruitment to clinical trials
• driving epidemiological modelling
• driving collaborative research
• tracking long-term outcomes of those on new generation modulator drugs (post-market surveillance)
• monitoring preventative care interventions as the population ages.

Nonetheless, of the 40 RDRs surveyed, the majority shared that the impact of their registry on the community was not measured or no direct impact had been made—mainly due to small sample sizes or a slow rollout. Of those registries measuring impact, the top three areas where this impact was demonstrated were changes in treatment outcomes, process of care and quality of care.

Key finding 4: Common challenges for RDRs

Together, data from the literature review, survey and interviews identified several challenges and enablers of running RDRs.

Challenges:

• insufficient funding and resources
• sustainability
• lack of government support
• recruitment
• governance
• transparency of data use
• data completeness
• limitations on the types of data that can be collected by organisations who are not registered health providers
• difficulties obtaining ethics approval, and barriers to collecting biological samples from rural and remote communities were also reported.

Enablers:

• dedicated staff
• contribution of clinicians’ time
• enthusiasm and commitment from a steering committee
• well defined cope and objectives
• site participation
• funding.

Interview respondents’ views for the way forward for rare disease registries in Australia

In line with the Action Plan, all interviewees were in favour of a national approach to RDRs. Discussions centred on:

• the need for a nationally consistent minimum dataset
• the need for a register of registries
• integration with other registries and international datasets
• interoperability
• most appropriate platforms
• increased participation in registries
• the community education on the value of registries
• data security and confidentiality.

What next?

These findings will inform recommendations and next steps for rare disease data collection in Australia. They will become the evidence-base for conversations with key decision makers to drive policy that supports RDRs and infrastructure to meet Action 3.1.4 in the Action Plan ‘Develop a national approach to person-centred rare disease registries to support national standards, best practice and minimum data sets’.

New online course for setting up a rare disease registry coming soon to RVA’s Online Education Portal

Thanks to the interest of RVA Partners, this work has inspired RVA to develop education around building a RDR. This online course will be co-developed with Dr Ruseckaite, Professor Ahern and other registry experts. RVA anticipates this course will be available on RVA’s Online Education Portal in late 2022.

Rare disease organisations are an important part of the Australian rare disease community. These organisations can understand, capture and communicate the lived experience of those impacted by a rare condition in a way no one else in the sector can. The rare disease community has specific and essential expertise in living with a rare condition and understanding the challenges, needs and burdens these conditions impose. This makes rare disease organisations and their leaders an essential part of the sector. 

“Rare disease organisations play a key role in raising disease awareness and providing critical person-centred information. These organisations are vital to the rare disease sector and often fill gaps in the system, not just in terms of awareness and education, but also care and support and, increasingly, in the research sphere.” — National Strategic Action Plan for Rare Diseases (2020)

The National Strategic Action Plan for Rare Diseases (the Action Plan) recognises the critical role rare disease organisations play in the rare disease sector. Providing support, education, advocacy and initiating research in the rare disease sector is complex.

To help address the need for additional support and resources to strengthen the rare disease sector, which is acknowledged in the Action Plan, Rare Voices Australia (RVA) is launching (the Guide).

Who Is the Guide for and How Can It Be Used?

The Guide is for both established rare disease organisations and those who are interested in setting up an organisation. For existing rare disease organisations, the Guide can be used in several ways to complement the current status, resources and development phase of your organisation. For those who are investigating how to establish an organisation, this is an easy to follow resource that covers the key areas to consider.

Chapter Breakdown

Chapter 1: Introduction to Rare Diseases, RVA, the Australian Landscape and the Action Plan
Chapter 2: Rare Disease Organisation Strategy
Chapter 3: The Vital Roles of Rare Disease Organisations
Chapter 4: Ethical Rare Disease Organisations
Chapter 5: Governance Foundations
Chapter 6: Funding Your Rare Disease Organisation
Chapter 7: Community Engagement
Appendices: Assessment Tools and Planning Template

Each section also contains information about the topic, links to relevant resources and a checklist or self-evaluation tool for identifying current strengths and areas for development.

Thank you to several of our RVA Partner organisations who contributed to the Guide throughout its evolution.

Download the Guide (PDF)

If you have any questions about this Guide or any other education-related matters, please reach out to RVA’s Education and Advocacy Manager: [email protected]

Rare Voices Australia (RVA) is looking to hire a Project Officer – Mental Health and Wellbeing (Maternity Leave Position).

The Project Officer – Mental Health and Wellbeing will play a key role in delivering the RArEST (Rare Awareness, Education, Support and Training) Project. The RArEST Project will contribute to the collaborative implementation of the National Strategic Action Plan for Rare Diseases. The successful candidate will work alongside the RVA team to identify the unmet needs of Australians living with a rare disease.

The Project Officer – Mental Health and Wellbeing will help to research, design and deliver customised and evidence-based mental health and wellbeing resources to a range of stakeholders in the rare disease community.

This position is suited to an individual with exceptional communication and people skills. Strong skills and experience in workshop facilitation and public speaking are required.

Download the full position description.

In 2022, Rare Voices Australia (RVA) is celebrating 10 years of rare disease advocacy. RVA’s 10th Anniversary Ambassador Program (the Ambassador Program) is one of several initiatives we are unveiling in 2022 to celebrate 10 years of rare disease advocacy. The overarching theme of the Ambassador Program is, Illuminating People Living with a Rare Disease.

We are thrilled to welcome our first group of official 2022 RVA Ambassadors and thank them for being involved in this new initiative. Each ambassador brings their own unique lived experience of rare disease. We will be sharing more about our RVA Ambassadors over the course of 2022 so be sure to follow RVA’s social media channels and sign up to receive our monthly eNewsletter.

RVA is currently seeking expressions of interest from Aboriginal and Torres Strait Islander people and people from culturally and linguistically diverse (CALD) backgrounds who are interested in becoming a 2022 RVA Ambassador (see the ambassador requirements). Those interested are encouraged to reach out to RVA: [email protected]

Introducing our 2022 RVA Ambassadors

Katie Alexander

Frequent falls, extreme fatigue and pain led to Katie’s diagnosis of Dermatomyositis. The rare disease destroys skin, muscles, tendons and organs reducing strength, dexterity and mobility. It can present with cancer, cardiac and auto-immune conditions. Myositis is fatal when inflammation scars the heart (Cardiomyopathy) and lungs (Interstitial Lung Disease). Katie’s Myositis symptoms were untreated for nearly 40 years until advanced disease prevented her from climbing stairs and rising from chairs. By then her muscles were wasting, dying and shortening. Katie had problems chewing, swallowing and speaking. Significant hair loss, skin rashes, peeling, lumps and blood spots changed her appearance. The aggressive disease was resistant to pharmacological treatment (steroids, chemotherapy, immunotherapy) until a kinase (JAK) inhibitor was trialled in 2021. Katie is very grateful for this respite and now shares her experiences of rare disease, disability and family violence through advocacy roles with the National Disability Insurance Agency (NDIA), Safe Steps, Peter MacCallum Cancer Hospital, Monash University and RMIT University.

Andrew Bannister

Andrew was born with three rare brain malformations – Periventricular Nodular Heterotopia (PVNH), Polymicrogyria and Cerebella Hypoplasia – as well as two other congenital malformations. His cerebellum is a quarter of the average size. These rare malformations have not stopped him achieving many things even though he has an intellectual and physical disability. Andrew’s determination to overcome the obstacles in his life inspires people, yet it is he who wants to help others by raising awareness about rare diseases. Among others, Andrew played a key role in the formation of the first Parliamentary Friends of People with Rare and Undiagnosed Diseases in Western Australia in 2021. Additionally, since 2020, Andrew has played a pivotal role in organising illuminations for Rare Disease Day in Australia.

Lachy Beckett

Lachy was diagnosed with a rare disease called Juvenile Dermatomyositis (JDM) when he was three years old. JDM is a form of Myositis affecting children. Myositis is a group of rare autoimmune diseases affecting the muscles. Lachy has been active as a volunteer in raising awareness for people with rare diseases for the past 10 years. He is currently involved in a business start-up with his family and in his spare time, loves playing guitar, reading and playing chess.

Ebony Callaghan

Ebony is 24 years old, lives with Intestinal Failure and requires Home Parenteral Nutrition. For the first few years of her life, no one noticed anything unusual apart from severe reflux and moderate constipation. At 11 she became unwell with what was thought to be a simple gastro bug, but after a week or two, she wasn’t better and was admitted to hospital for investigation. At 17 she was eventually diagnosed with Superior Mesenteric Artery Syndrome (SMAS), a very rare and life-threatening digestive system disorder that occurs when the duodenum (the first part of the small intestine) is compressed between two arteries (the aorta and superior mesenteric artery). Ebony feels incredibly lucky to have been chosen to be an RVA Ambassador and looks forward to sharing more of her story and lived experience.

Nathan Charles

At three months of age, Nathan was diagnosed with Cystic Fibrosis (CF) and his parents were told he may not make it to his 10^th birthday. Nathan’s resolve never faltered despite a future that was likely to be filled with challenges. His passion for rugby eventually saw him living out his childhood dream of playing for Australia in the Wallabies’ second test against France at the age of 25. Throughout his career and life, Nathan has been adamant not to be defined by CF and has never viewed his condition as an obstacle to success in any facet of life. Today, Nathan is the Chief Executive Officer of Rugby WA. 

Tim Fulton

Tim was formally diagnosed with Adult-onset Still’s disease (Still’s disease) in 2016 at the age of 22. Still’s disease is a rare systemic, auto-inflammatory condition that affects between one in 100,000 to one in 1,000,000 people globally. In August 2020, to stay on top of his mental health, combat the effects of calcium leaching from medication and driven by his desire to encourage people, in particular the rare disease community, Tim set himself the goal of running 100km before Rare Disease Day — a big audacious goal given his health! He began the Instagram page Running Rare to document his progress and this has evolved to the development of an accompanying website to encourage and uplift the rare disease community. Tim is a big believer of living with a ‘it is possible’ attitude. This doesn’t mean you’re naive to the reality of your circumstances, but it does encourage and motivate you to think about what might make something possible — and that is such an important first step.

Tammie Rees

Tammie is the mother of two children and lives in regional Victoria. Her youngest is 5 years old next and was born and diagnosed in 2017 with Maple Syrup Urine Disease. Tammie says it’s been a very big learning journey but one in which her family has managed to find their feet and now are ready to have their voices heard on important issues such as inclusion, research, cures and anything else they can do to help. She is excited to see what we can achieve together. When Tammie is not busy working and with family life, she enjoys running.

Beck Webber

In 2014, Beck noticed small micro changes in the way her body operated, which was noted in her medical files. On Christmas night in 2017, she fell down a flight of 11 stairs after losing her feet on the top step. This resulted in her spending the next 12 months with a crushed disc and surgery to replace the disc and rods in her back. In 2020, Beck noticed she was becoming highly fatigued, sleeping all day and her legs either felt like jelly or stiff as a board. After a blood test was sent to the United States of America for genetic testing, she was eventually diagnosed with Spinocerebellar ataxia type 36 (SCA36). Beck is looking forward to ‘illuminating’ the rare disease cohort in a more public manner and sharing her experiences as a para equestrian athlete.

Renae Wood

Renae is 27 and is based in Brisbane, Queensland. She was born with a rare disease called Epidermolysis Bullosa (EB), which is a condition that causes fragile, blistering skin that also tears easily and scars. The gene fault that caused Renae’s EB is rare and is also responsible for her diagnoses of alopecia and dilated cardiomyopathy. Living with rare disease can feel isolating and can make life unpredictable, which is why Renae feels it’s important for those living with a rare disease to share their experiences. Renae’s hope is to empower people to share their stories, so that we are reminded that we’re not alone but are part of one brave community!

On Tuesday, 29 March 2022, the Hon Josh Frydenberg MP (Treasurer of Australia) announced the Morrison Government’s 2022-23 Federal Budget, which included a record investment in Australia’s health system with a total commitment of $537 billion over the next four years.

As the national peak body for Australians living with a rare disease, Rare Voices Australia (RVA) attended the Department of Health’s Portfolio Briefing webinar presentation and Q&A with the Hon Greg Hunt MP (Minister for Health and Aged Care); the Hon Dr David Gillespie MP (Minister for Regional Health); the Hon David Coleman MP (Assistant Minister to the Prime Minister for Mental Health and Suicide Prevention); and Senator the Hon Richard Colbeck (Minister for Senior Australians and Aged Care Services). The session was facilitated by Dr Brendan Murphy, Secretary of the Department of Health.

In our Budget Statement, RVA has highlighted areas of the Budget we believe are most relevant to Australians living with a rare disease and the rare disease sector.

Download RVA’s Budget Statement [PDF]

In 2022, Rare Voices Australia (RVA) is celebrating 10 years of rare disease advocacy. Thank you to everyone who contributed to RVA’s work over the last decade. From former RVA Board Directors and Scientific and Medical Advisory Committee members to RVA Partners, former staff and all stakeholders, we acknowledge your ongoing support. While much work still needs to be done to achieve the best possible outcomes for Australians living with a rare disease, we are incredibly proud of RVA’s work and achievements to date.

10^th Anniversary Ambassador Program

RVA will be unveiling several initiatives throughout the year to celebrate this milestone, including RVA’s 10^th Anniversary Ambassador Program (the Ambassador Program). The overarching theme of the Ambassador Program is: Illuminating People Living with a Rare Disease. The Ambassador Program will provide people living with a rare disease (which includes carers and families) and those with professional experience of rare diseases, with the opportunity to become an official RVA Ambassador.

We are currently seeking expressions of interest (EOIs) from those interested. We are looking for 10 ambassadors for our 2022 Ambassador Program. Before applying, please read the below information to see if you are a suitable candidate.

Ambassador requirements

• Lived or professional experience of rare diseases
• Demonstrated use of personal network and platforms to advocate for the best outcomes for the broader rare disease community
• A demonstrated supporter of RVA
• Willing to review and consider signing RVA’s Ambassador Agreement, which can be provided on request to those interested
• Aligned with RVA’s ‘ways of working’ as an RVA Ambassador, which are outlined below

We are person-centred

We want the outcomes that are best for each person as an individual. We will be driven by the needs of each person and by what works best for them. We won’t impose our assumptions on people.

We will actively build and maintain partnerships

We are the voice of the sector, magnifying the voices of all stakeholders that share our goals. We recognise that achieving the transformation we want to see in Australia will require us working in partnership with stakeholders.

We aim for a unified voice

We recognise that without a unified voice, the rare disease sector cannot be successful in achieving the support for people living with a rare disease that we need. As a result, we will prioritise consultation and conversation within the sector to ensure that our voice to policymakers and the broader community is as unified as possible.

We work for equity of access and participation

We believe that equity of access and participation is vital for all people living with a rare disease in Australia. In our initiatives, we will ensure that equity is a key factor in our planning and design. And in our advocacy, the principles of equity will be foremost in our messaging.

We will equip and empower

We aim to equip and empower organisations and people to help them advocate and work for themselves.

We are solutions and results oriented

We want to see results for people living with a rare disease in Australia. We are not going to be bound to theoretical models. We will adopt what works and will test our initiatives against the results they deliver.

We are credible

We recognise that our effectiveness is only as good as our credibility and trustworthiness. We will ensure that all of our actions and words build our credibility, rather than erode it. We recognise that trust takes a long time to build but can be quickly lost.

We will adopt a systemic focus

We are uniquely positioned to engage in systemic advocacy. Effective reform to systems and processes must be prioritised to reduce individuals and groups repeatedly facing common challenges. This is vital to achieving sustainable change at scale.

Ambassador opportunities

RVA Ambassadors will have the opportunity to:

• Share their personal story, which will be featured as a written article on RVA’s website. We will also invite ambassadors to film a short video to complement their written story. Each personal story will also be promoted in an edition of our monthly eNewsletter and RVA’s social media channels.
• Send a copy of the National Strategic Action Plan for Rare Diseases (the Action Plan),to their local Federal and State Members of Parliament (MPs) as an official RVA Ambassador. Ambassadors are invited to organise a meeting with their local MPs to speak about their personal experience of living with a rare disease and rare diseases in general.
• Attend RVA events in 2022 in a volunteer capacity, where appropriate.
• Use their networks (e.g. social media, newsletter databases etc.) to cross promote RVA’s work.
• Contribute to relevant media stories from the perspective of an individual living with a rare disease or as a professional who has worked with rare diseases.

All RVA Ambassadors will receive a Welcome Pack. RVA will also support each ambassador in their role as needed.

10^th Anniversary Ambassador Program Welcome Pack

• A brief introduction to RVA and how we work, alongside training as required
• Access to RVA’s Online Education Portal
• One hard copy of the Action Plan and complementary communications materials
• One RVA branded hat

Interested in becoming an official RVA Ambassador? Please complete the EOI below and a member of our team will be in touch shortly.

Please direct any questions regarding RVA’s 10^th Anniversary Ambassador Program to: [email protected]

Rare Disease Day will be marked on 28 February 2022. As reported in December eNews, Rare Voices Australia (RVA) has been actively contributing to the development of the global Rare Disease Day campaign. The main objective of Rare Disease Day is to raise awareness among the general public and decision-makers about rare diseases and their impact on people’s lives.

Rare Metabolic Disease Workforce White Paper

RVA will leverage Rare Disease Day to help promote the launch of the much-anticipated Rare Metabolic Disease Workforce White Paper. ‘Sustainable systems and workforce’ is one of three foundation principles of the National Strategic Action Plan for Rare Diseases (the Action Plan). This work will help to progress one of the key priorities in the Action Plan: ‘Develop a national rare disease workforce strategy that responds to current and future demands, including the impact of genomics’.

Thank you to the Project Steering Committee, RVA Partners, people living with a rare metabolic condition, clinicians, industry and everyone else who contributed to this critical study. We look forward to sharing the White Paper findings this month.

Landmark Illuminations in Australia

Landmark illuminations will again be a focus on Rare Disease Day. We thank our small team of volunteers who have been working over the last few months to secure these illuminations. Your efforts are very much appreciated!

Click here to see the current list of landmarks around Australia as of 23 February 2022 that will be illuminating on 28 February.

RVA has put together a Media Pack for any media activity you or your organisation would like to engage in ahead of Rare Disease Day for the illuminations.

Click here to download the media release template [Word].

You can download social media assets by state and platform here.

To download a one-pager with more information about rare diseases, Rare Disease Day and RVA, click here.

You can direct any media looking for more information about rare diseases here. All Rare Disease Day assets can be downloaded from the official Rare Disease Day website.

RVA Partners that would like assistance with any planned media activities are encouraged to reach out to RVA directly: [email protected]

If you take pictures of the illuminations or other Rare Disease Day activities and would like to share them, please email: [email protected]

Alternatively, you can tag RVA on social media. Please ensure you use the official hashtag: #RareDiseaseDay

Global Rare Disease Day Event — World Expo in Dubai

RVA’s Chief Executive Officer, Nicole Millis, will speak at the global 2022 Rare Disease Day event at the World Expo in Dubai, organised by the NGO Committee for Rare Diseases, Ågrenska Foundation, Rare Diseases International and EURORDIS-Rare Diseases Europe. The event will celebrate the adoption of the United Nations Resolution on ‘Addressing the Challenges of Persons Living with a Rare Disease and Their Families’ (the Resolution) and discuss opportunities for implementation at the international, regional and national levels. Nicole will be speaking on a panel and sharing RVA’s work in driving national advocacy and the Resolution’s potential impact in Australia.

This event marks the Fourth High-Level meeting of the NGO Committee for Rare Diseases and will be held on 28 February 2022, from 10.00 – 16.30 Gulf Standard Time (GST) at the Sweden Pavilion, World Expo, Dubai, United Arab Emirates.

Rare Voices Australia (RVA) has continued to actively advocate for systemic improvements to the National Disability Insurance Scheme (NDIS), to ensure the program can better respond to the unique needs and challenges of people living with a disability caused by rare disease. Through this sustained and ongoing advocacy, RVA was invited to participate in an interactive virtual roundtable meeting with the National Disability Insurance Agency (NDIA) and RVA Partner organisations on 1 December. The NDIA limited the number of places available at the workshop to ensure it remained interactive.

The following RVA Partners joined RVA at the roundtable:

• Angelman Support Association Australia
• Battens Disease Support and Research Association
• Fragile X Association Australia
• Huntington’s NSW and ACT
• Mito Foundation
• Muscular Dystrophy Foundation Australian
• SCN2A

The two-hour session provided a platform for the NDIA to hear directly from the rare disease community, so the NDIA can be better informed about the functional impacts and support requirements of people with rare diseases who seek to access NDIS services. The roundtable covered three broad areas of the NDIS for discussion, which had been identified as key pain points for the rare disease community:

• Access Pathway
• Planning
• Assistive Technology

These focus areas align with Implementation step 2.1.2.2 of the National Strategic Action Plan for Rare Diseases, which prioritises the need to fast track access to the NDIS and ensure participants are able to secure the appropriate support services to meet the evolving needs of people with rare diseases and their families.

For RVA and attending RVA Partners, the session enabled a robust discussion with the administrators of the NDIS about the unique challenges in eligibility, access and planning experienced by rare disease applicants and participants. While RVA Partners represented a broad range of rare diseases, insights into their communities’ lived experiences with the NDIS clearly demonstrated the extensive policy issues that currently exist within the system, that impact all people with rare diseases. To select participants who could represent a broad range of rare diseases, RVA sought Expressions of Interest (EOI) from RVA Partner organisation leaders. RVA then considered:

• The EOI lodged
• Broad representation of the rare disease community
• Diverse range of experiences with the NDIS
• Demonstrated alignment with RVA’s advocacy approach
• Willingness and ability to represent the broader rare disease community

Although this roundtable session was the first-of-its-kind to be held between the rare disease sector and the NDIA, RVA was able to raise the need for creating a fit-for-purpose mechanism to facilitate ongoing dialogue between the two groups; and we expect similar sessions may be held during 2022. RVA thanks the attending RVA Partner organisations for their participation at this session and their commitment to improving the NDIS experience for people living with rare diseases. We look forward to keeping all stakeholders updated on the outcomes of this NDIA roundtable and communicating with RVA Partner organisations regarding potential future opportunities to contribute to this systemic advocacy.

Rare Voices Australia (RVA) is seeking non-executive directors to join the RVA Board. Successful applicants will bring experience, skills and capabilities that contribute to the governance of RVA and enhance its advocacy for the best outcomes for Australians living with a rare disease.

RVA remains committed to board diversity and inclusion. Specific experience in fundraising or political/government engagement would be viewed favourably but is not essential. Applicants should complete and send an Expression of Interest form and their CV to Nicole Millis, RVA’s Chief Executive Officer: [email protected]. Board meetings are held via teleconference every two months and involve up to two hours of pre-reading. A duty statement for RVA Directors can be provided on request.

Our high calibre RVA Board oversees the organisation’s strategic purpose and direction and comprises dedicated and passionate volunteers, including those with lived experience. The board consists of those with a professional skill set relevant to the organisation including legal, financial, medical and scientific expertise. You can find more information about RVA’s governance framework and reporting here.

RVA is the national peak body for Australians living with a rare disease. Our person-centred focus sees us working with all key stakeholders including people living with a rare disease, governments, key peak bodies, researchers, clinicians and industry. You can read more about RVA’s purpose, including our Vision and Mission here.

The Australian Government commissioned RVA to lead the collaborative development of the National Strategic Action Plan for Rare Diseases (the Action Plan) in 2018. The Action Plan was launched in 2020 with bipartisan support after an extensive multi-stakeholder consultation process. RVA is now leading the Action Plan’s collaborative implementation.

Please direct any queries you may have about these board positions to RVA’s CEO.